KPV: Evidence, Legal Status, and Safety
KPV is a tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), sold for gut and skin inflammation. The evidence is entirely preclinical: real, published animal and cell studies show it blocks NF-kB inflammatory signaling and reduces colitis in mice, but no completed human clinical trial exists. It has no FDA-approved use and no established legal pathway for human use; it is sold as an unregulated research chemical.
Understand what's actually being sold A 3-amino-acid fragment (lysine-proline-valine) of alpha-MSH that retains some of the parent hormone's anti-inflammatory activity, marketed for gut healing (IBD-adjacent claims) and skin or topical use.
Fragment peptides derived from a larger hormone do not automatically inherit the parent hormone's full safety or efficacy profile.
See what the evidence actually shows Nanomolar concentrations of KPV inhibited NF-kB and MAP kinase inflammatory signaling and reduced DSS- and TNBS-induced colitis severity in mice; transport into cells occurs via the PepT1 di/tripeptide transporter. This is animal and cell data; no completed human trial was found.
Real, published preclinical evidence is not the same as clinical proof; this stays Tier C until human trial data exists.
Know where it actually stands Not FDA-approved for any human use; no prescription pathway exists. On 23 Jul 2026, the FDA's Pharmacy Compounding Advisory Committee recommended KPV for compounding, but that recommendation is advisory only: nothing is legal today. Sold almost exclusively as an unregulated research chemical, not for human consumption. Some cosmetic formulations reference KPV as a topical ingredient, a separate, lower-bar regulatory category.
A cosmetic-ingredient listing is not equivalent to a reviewed medical use.
Know the real risk No human safety data exists in any completed trial. Unregulated research-chemical sourcing carries the standard purity and contamination risk common to this whole category.
Without completed human trials, there is no independent basis for a safety claim in either direction.
The evidence base is animal and cell data.
View sources
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone considering KPV who wants the honest evidence before discussing it with a clinician
- Readers researching gut-inflammation peptides who have seen IBD-adjacent claims
- Readers comparing KPV to FDA-approved peptides like semaglutide or tesamorelin
Cautions
- Entirely preclinical evidence; no completed human clinical trial exists
- Not FDA-approved for any human use; sold as an unregulated research chemical
- No completed human trial registry entry was found for KPV in this research pass
- Educational only, not medical advice